Irenic Capital Management LP Takes $4.75 Million Position in AnaptysBio, Inc. $ANAB

Irenic Capital Management LP bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 70,447 shares of the biotechnology company’s stock, valued at approximately $4,755,000.

Other hedge funds have also added to or reduced their stakes in the company. Persistent Asset Partners Ltd bought a new stake in AnaptysBio in the 2nd quarter valued at $39,000. Smartleaf Asset Management LLC increased its position in AnaptysBio by 5,864.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock worth $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC increased its position in AnaptysBio by 54.6% during the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after buying an additional 473 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in shares of AnaptysBio by 940.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in shares of AnaptysBio by 987.3% during the fourth quarter. Royal Bank of Canada now owns 1,718 shares of the biotechnology company’s stock worth $83,000 after buying an additional 1,560 shares in the last quarter.

AnaptysBio Stock Performance

NASDAQ:ANAB opened at $56.80 on Friday. The stock has a fifty day moving average price of $58.18 and a 200-day moving average price of $59.19. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -52.59 and a beta of 0.71. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ANAB shares. Weiss Ratings reissued a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. Barclays lifted their price objective on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Wall Street Zen downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research lowered shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Finally, Leerink Partners set a $90.00 target price on shares of AnaptysBio in a research report on Friday, May 15th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.